中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
15期
74-75
,共2页
替格瑞洛%氯吡格雷抵抗%冠状动脉介入
替格瑞洛%氯吡格雷牴抗%冠狀動脈介入
체격서락%록필격뢰저항%관상동맥개입
ticagrelor%clopidogrel%coronary intervention
目的：观察氯吡格雷抵抗的经皮冠状动脉介入（PCI）治疗患者采用替格瑞洛治疗的临床效果及安全性。方法选取医院收治的 PCI患者80例，均经血栓弹力图（TEG）检查证实为氯吡格雷抵抗，随机分成试验组和对照组，各40例。对照组继续口服硫酸氢氯吡格雷片（75 mg，每日1次），试验组改用口服替格瑞洛片（90 mg，每日2次），同时服用阿司匹林肠溶片（100 mg，每日1次）。两组均连续用药3个月，随访3个月。结果治疗3个月后，对照组血小板计数为（198.21±86.62）×109/ L，血小板聚集率为（44.51±8.65）%，二磷酸腺苷最大聚集时间为（63.21±56.21）s，二磷酸腺苷最大聚集率为（35.61±6.95）%，与试验组的(188.54±83.62)×109/ L、（36.32±5.63）%、（178.51±89.65）s、（65.12±8.21）%相比，差异均有统计学意义（ P <0.05）；随访3个月，试验组心血管事件发生率为5.00%，显著低于对照组的22.50%（ P <0.05）；试验组出血发生率为2.50%，低于对照组的10.00%（ P >0.05）。结论替格瑞洛治疗氯吡格雷抵抗的 PCI 患者，疗效满意，安全性高，值得临床应用。
目的：觀察氯吡格雷牴抗的經皮冠狀動脈介入（PCI）治療患者採用替格瑞洛治療的臨床效果及安全性。方法選取醫院收治的 PCI患者80例，均經血栓彈力圖（TEG）檢查證實為氯吡格雷牴抗，隨機分成試驗組和對照組，各40例。對照組繼續口服硫痠氫氯吡格雷片（75 mg，每日1次），試驗組改用口服替格瑞洛片（90 mg，每日2次），同時服用阿司匹林腸溶片（100 mg，每日1次）。兩組均連續用藥3箇月，隨訪3箇月。結果治療3箇月後，對照組血小闆計數為（198.21±86.62）×109/ L，血小闆聚集率為（44.51±8.65）%，二燐痠腺苷最大聚集時間為（63.21±56.21）s，二燐痠腺苷最大聚集率為（35.61±6.95）%，與試驗組的(188.54±83.62)×109/ L、（36.32±5.63）%、（178.51±89.65）s、（65.12±8.21）%相比，差異均有統計學意義（ P <0.05）；隨訪3箇月，試驗組心血管事件髮生率為5.00%，顯著低于對照組的22.50%（ P <0.05）；試驗組齣血髮生率為2.50%，低于對照組的10.00%（ P >0.05）。結論替格瑞洛治療氯吡格雷牴抗的 PCI 患者，療效滿意，安全性高，值得臨床應用。
목적：관찰록필격뢰저항적경피관상동맥개입（PCI）치료환자채용체격서락치료적림상효과급안전성。방법선취의원수치적 PCI환자80례，균경혈전탄력도（TEG）검사증실위록필격뢰저항，수궤분성시험조화대조조，각40례。대조조계속구복류산경록필격뢰편（75 mg，매일1차），시험조개용구복체격서락편（90 mg，매일2차），동시복용아사필림장용편（100 mg，매일1차）。량조균련속용약3개월，수방3개월。결과치료3개월후，대조조혈소판계수위（198.21±86.62）×109/ L，혈소판취집솔위（44.51±8.65）%，이린산선감최대취집시간위（63.21±56.21）s，이린산선감최대취집솔위（35.61±6.95）%，여시험조적(188.54±83.62)×109/ L、（36.32±5.63）%、（178.51±89.65）s、（65.12±8.21）%상비，차이균유통계학의의（ P <0.05）；수방3개월，시험조심혈관사건발생솔위5.00%，현저저우대조조적22.50%（ P <0.05）；시험조출혈발생솔위2.50%，저우대조조적10.00%（ P >0.05）。결론체격서락치료록필격뢰저항적 PCI 환자，료효만의，안전성고，치득림상응용。
Objective To evaluate the ticagrelor treatment of percutaneous coronary intervention in patients with the clinical effects of clopidogrel resistance. Methods In our hospital percutaneous coronary intervention in patients with 80 cases, patients were selected by the TEG (thrombelastograph) were confirmed as clopidogrel resistance. By randomly selected cases will be divided into experimental and control groups with 40 patients in the control group continued clopidogrel therapy(75 mg / d, for 7 d), the experimental group received ticagrelor therapy (90 mg, 2 times / d, for 7 d), aspirin(100 mg, 1 times / d), for 3 weeks, follow - up 3 months. Results Platelet count was (198. 21 ± 86. 62) × 109 / L, platelet aggregation rate (44. 51 ± 8. 65)% , adenosine diphosphate maximum aggregate time (63. 21 ± 56. 21 ) s, the maximum aggregate rate of adenosine diphosphate It was (35. 61 ± 6. 95)% , and the control group (188. 54 ± 83. 62) × 109 / L, (36. 32 ± 5. 63)% , (178. 51 ± 89. 65) s, (65. 12 ± 8. 21)% , the difference was statistically significant( P < 0. 05) . Experimental cardiovascular events was 5. 00% , significantly lower than the 22. 50% in the control group( P < 0. 05); the experimental group, bleed-ing was 2. 50% , down from 10. 00% in the control group, but no significant difference between groups( P > 0. 05) . Conclusion Tica-grelor therapy after percutaneous coronary intervention in patients with clopidogrel resistance results were satisfactory, safe, large hospitals at all levels learn applications.
